Posted by Michael Wonder on 30 Nov 2021
Lynparza granted priority review in the US for BRCA mutated HER2 negative high risk early breast cancer
30 November 2021 - First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting.
AstraZeneca’s supplemental new drug application for Lynparza (olaparib) has been accepted and granted priority review in the US for the adjuvant treatment of patients with BRCA mutated HER2 negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.
